TrialRheumatology (Oxford, England)2026

Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial.

Pauline M E T Bovens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.